CVS Related Analyst Comments
-
Wells Fargo Starts CVS Caremark (CVS) at Outperform
-
Cardinal Health (CAH) Needs CVS Renewal After Walgreen Loss - Analyst
-
Goldman Sachs Downgrades CVS Caremark (CVS) to Neutral, Few Catalysts
-
Jefferies Boosts Numbers on CVS (CVS) Post Analyst Day
-
CVS (CVS) Taking Walgreen (WAG) Share - Analyst
-
Jefferies Lifts Numbers on CVS Caremark (CVS) on Strong Q3
-
Jefferies Cuts PT on Green Dot (GDOT), Sees Another Large Client May Move to AmEx (AXP)
-
LabCorp (LH) Could See a Hit from Aetna/Coventry Health Deal
-
CVS Caremark (CVS) Will Come Out A Winner in Aetna/Coventry Deal
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); OraQuick HIV-OTC Test in 30,000 Locations
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Positive on Shares After Mee ing
-
UBS Maintains a 'Buy' on Cardinal Health (CAH); Color on Safeway Contract
-
UBS Raises Numbers on CVS Caremark (CVS); Comments From Conference Call
-
Jefferies Boosts Price Target on CVS Caremark (CVS) After Q1 Results
-
UBS on Healthcare Distribution - PBMs: Implications from SXCI/CHSI Deal
-
Jefferies Maintains a 'Buy' on CVS Caremark (CVS); A Superior Model
-
UBS Maintains a 'Buy' on CVS Caremark (CVS); Raising FY12/13 EPS Estimates
-
Q4 Preview: CVS (CVS) Quarter Should Be Telegraphed But Investors Will Want Details
-
Citi Adds CVS (CVS) to 'Top Picks Live' List Ahead of Q4 Results
-
UBS Maintains a 'Buy' on Walgreen (WAG); January Comps Will Represent First Month Without ESRX
-
UBS Maintains a 'Neutral' on CVS Caremark (CVS); Raising ‘13 EPS for Generics/PBM Mojo
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
Goldman Sachs Lifts Price Target On CVS Caremark (CVS)
-
UBS Maintains a 'Buy' on CVS Caremark (CVS); Post-Call: Plenty of Positive Datapoints
-
Jefferies Raises Price Target on CVS Caremark (CVS), Sees Upside Potential
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); 3Q11 Earnings Preview
-
Citi Says Buy CVS (CVS) Ahead of Q3 Results as Walgreen/Express Scripts Talks Ongoing
-
Jefferies Cuts Price Target on Walgreen (WAG), Encourges a Settlement with Express Scripts (ESRX)
-
UBS Maintains a 'Neutral' on Rite-Aid (RAD); Raising PT on Business Momentum
-
Q2 Preview: CVS (CVS) Looking to PBM to Continue Strong Results
-
CVS (CVS) Shares Positive as JPMorgan Adds to 'Focus List'
-
Barclays Maintains an 'Equalweight' on Walgreen (WAG); Drawing a Line in the Sand
-
FBR Capital Maintains an 'Outperform' on Medco Health (MHS); Removes as Top Pick
-
Credit Suisse Lifts Price Target On CVS Caremark (CVS)
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Predictability Seems to Have Returned
-
Jefferies Raises Price Target on CVS Caremark (CVS) Following Comments from Larry Merlo
-
Q1 Preview: CVS (CVS) May Have Prescription for Beat on Aetna Contract
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); 1Q11 Earnings Preview
-
Jefferies Issues Positive Comments On CVS Caremark (CVS) Following Survey
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Review of Recent Management Meetings
-
Goldman Sachs Doesn't Think Break-Up of CVS Caremark (CVS) Is a Great Idea
-
Canaccord Genuity on Rite Aid (RAD): RAD
-
Canaccord Genuity Morning Coffee on Walgreen (WAG) and Catalyst Health (CHSI): Breaking Up...Not So Hard To Do
-
Barclays on Healthcare Services: Weekly Flu Clues Review
-
Credit Suisse Sees Value Creation From UnitedHealth's (UNH) PBM
-
Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Goal: Achieve a Return on Caremark
-
Barclays Maintains an 'Overweight' on Catalyst Health Solutions (CHSI); 'Hurry up and Wait': CVS Comments Lead to Update on Maryland PBM Contract Protest
-
Aetna (AET) Bounces on Sharp Dividend Increase, FY11 EPS Forecast; Analysts Weign In
-
Credit Suisse Adds CVS (CVS) to Focus List, Removes Kroger (KR)
-
UBS Maintains a 'Buy' on CVS Caremark (CVS); Frustrations Remain, But Cheap Here
Back to CVS Stock Lookup
